News | May 29, 2024
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
